Patent: 6,858,409
✉ Email this page to a colleague
Summary for Patent: 6,858,409
Title: | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
Abstract: | Compounds are disclosed having the general formula R.sub.1 --X--R.sub.2, wherein R.sub.1 and R.sub.2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R.sub.1 and R.sub.2 may be the same or different. Preferred R.sub.1 and R.sub.2 groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor. |
Inventor(s): | Thompson; Robert C. (Boulder, CO), Hannum; Charles H. (Sunnyvale, CA), Eisenberg; Stephen P. (Boulder, CO), Arend; William P. (Denver, CO), Joslin; Fenneke G. (Denver, CO), Sommer; Andreas (Danville, CA) |
Assignee: | Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) |
Application Number: | 08/482,283 |
Patent Claims: | see list of patent claims |
Details for Patent 6,858,409
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | November 14, 2001 | ⤷ Sign Up | 2022-02-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,858,409
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 911981 | ⤷ Sign Up |
South Africa | 905593 | ⤷ Sign Up |
South Africa | 894052 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 9534326 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 9216221 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 8911540 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |